[1]
|
Leong, S.P., Shen, Z.Z., Liu, T.J., Agarwal, G., Tajima, T., Paik, N.S., Sandelin, K., Derossis, A., Cody, H. and Foulkes, W.D. (2010) Is Breast Cancer the Same Disease in Asian and Western Countries? World Journal of Surgery, 34, 2308-2324. https://doi.org/10.1007/s00268-010-0683-1
|
[2]
|
Wilkinson, L. and Gathani, T. (2022) Understanding Breast Cancer as a Global Health Concern. The British Journal of Radiology, 95, Article ID: 20211033. https://doi.org/10.1259/bjr.20211033
|
[3]
|
Mollon, L.E. anderson, E.J., Dean, J.L., et al. (2020) A Systematic Lit-erature Review of the Prognostic and Predictive Value of PIK3CA Mutations 17 in HR+/HER2− Metastatic Breast Can-cer. Clinical Breast Cancer, 20, e232-e243.
https://doi.org/10.1016/j.clbc.2019.08.011
|
[4]
|
Mosele, F., Stefanovska, B., Lusque, A., et al. (2020) Outcome and Molecular Landscape of Patients with PIK3CA- Mutated Metastatic Breast Cancer. Annals of Oncology, 31, 377-386.
https://doi.org/10.1016/j.annonc.2019.11.006
|
[5]
|
Hennessy, B.T., Smith, D.L., Ram, P.T., Lu, Y. and Mills, G.B. (2005) Exploiting the PI3K/AKT Pathway for Cancer Drug Discovery. Nature Reviews Drug Discovery, 4, 988-1004. https://doi.org/10.1038/nrd1902
|
[6]
|
Vivanco, I. and Sawyers, C.L. (2002) The Phosphatidylinositol 3-Kinase AKT Pathway in Human Cancer. Nature Reviews Cancer, 2, 489-501. https://doi.org/10.1038/nrc839
|
[7]
|
Cantley, L.C. (2002) The Phosphoinositide 3-Kinase Pathway. Science, 296, 1655-1657.
https://doi.org/10.1126/science.296.5573.1655
|
[8]
|
Arafeh, R. and Samuels, Y. (2019) PIK3CA in Cancer: The Past 30 Years. Seminars in Cancer Biology, 59, 36-49.
https://doi.org/10.1016/j.semcancer.2019.02.002
|
[9]
|
Vitale, S.R., Martorana, F., Stella, S., et al. (2021) PI3K In-hibition in Breast Cancer: Identifying and Overcoming Different Flavors of Resistance. Critical Reviews in Oncolo-gy/Hematology, 162, Article ID: 103334.
https://doi.org/10.1016/j.critrevonc.2021.103334
|
[10]
|
Katso, R., Okkenhaug, K., Ahmadi, K., et al. (2001) Cellular Function of Phosphoinositide 3-Kinases: Implications for Development, Homeostasis, and Cancer. Annual Review of Cell and Developmental Biology, 17, 615-675.
https://doi.org/10.1146/annurev.cellbio.17.1.615
|
[11]
|
Vanhaesebroeck, B., Guillermet-Guibert, J., Graupera, M. and Bilanges, B. (2010) The Emerging Mechanisms of Isoform-Specific PI3K Signalling. Nature Reviews Molecular Cell Biology, 11, 329-341. https://doi.org/10.1038/nrm2882
|
[12]
|
Samuels, Y. and Velculescu, V.E. (2004) Oncogenic Mutations of PIK3CA in Human Cancers. Cell Cycle, 3, 1221- 1224. https://doi.org/10.4161/cc.3.10.1164
|
[13]
|
Koboldt, D.C., Fulton, R., McLellan, M., et al. (2012) Comprehensive Molecular Portraits of Human Breast Tumours. Nature, 490, 61-70. https://doi.org/10.1038/nature11412
|
[14]
|
Martínez-Sáez, O., Chic, N., Pascual, T., et al. (2020) Frequency and Spectrum of PIK3CA Somatic Mutations in Breast Cancer. Breast Cancer Research, 22, 45. https://doi.org/10.1186/s13058-020-01284-9
|
[15]
|
Samuels, Y., Diaz, L.A., Schmidt-Kitler, O., et al. (2005) Mutant PIK3CA Promotes Cell Growth and Invasion of Human Cancer Cells. Cancer Cell, 7, 561-573. https://doi.org/10.1016/j.ccr.2005.05.014
|
[16]
|
Guo, X.N., RajPut, A., Rose, R., et al. (2007) Mutant PIK3CA-Bearing Colon Cancer Cells Display Increased Metastasis in Orthotopic Model. Cancer Research, 67, 5851-5858. https://doi.org/10.1158/0008-5472.CAN-07-0049
|
[17]
|
Dunlap, J., Le, C., Shukla, A., et al. (2010) Phosphatidylinositol-3-Kinase and AKT1 Mutations Occur Early in Breast Carcinoma. Breast Cancer Research and Treatment, 120, 409-418. https://doi.org/10.1007/s10549-009-0406-1
|
[18]
|
Dumont, A.G., Dumont, S.N. and Trent, J.C. (2012) The Favorable Impact of PIK3CA Mutations on Survival: An Analysis of 2587 Patients with Breast Cancer. Chinese Journal of Cancer, 31, 327-334.
https://doi.org/10.5732/cjc.012.10032
|
[19]
|
Pang, B., Cheng, S., Sun, S.-P., et al. (2015) Prognostic Role of PIK3CA Mutations and Their Association with Hormone Receptor Expression in Breast Cancer: A Meta-Analysis. Sci-entific Reports, 4, Article No. 6255.
https://doi.org/10.1038/srep06255
|
[20]
|
Sobhani, N., Roviello, G., Corona, S.P., et al. (2018) The Prognostic Value of PI3K Mutational Status in Breast Cancer: A Meta-Analysis. Journal of Cellular Biochemistry, 119, 4287-4292. https://doi.org/10.1002/jcb.26687
|
[21]
|
Fan, H., Li, C., Xiang, Q., et al. (2018) PIK3CA Mutations and Their Re-sponse to Neoadjuvant Treatment in Early Breast Cancer: A Systematic Review and Meta-Analysis. Thoracic Cancer, 9, 571-579.
https://doi.org/10.1111/1759-7714.12618
|
[22]
|
Burstein, H.J. (2020) Systemic Therapy for Estrogen Recep-tor-Positive, HER2-Negative Breast Cancer. The New England Journal of Medicine, 383, 2557-2570. https://doi.org/10.1056/NEJMra1307118
|
[23]
|
Clark, G.M., Osborne, C.K. and McGuire, W.L. (1984) Correlations between Estrogen Receptor, Progesterone Receptor, and Patient Characteristics in Human Breast Cancer. Journal of Clinical Oncology, 2, 1102-1109.
https://doi.org/10.1200/JCO.1984.2.10.1102
|
[24]
|
Colleoni, M., Rotmensz, N., Maisonneuve, P., et al. (2012) Outcome of Special Types of Luminal Breast Cancer. Annals of Oncology, 23, 1428-1436. https://doi.org/10.1093/annonc/mdr461
|
[25]
|
Sabine, V., Crozier, C., Drake, C., Piper, T., et al. (2012) PIK3CA Mutations Are Linked to PgR Expression: A Tamoxifen Exemestane Adjuvant Multinational (TEAM) Pathology Study. Cancer Research, 72, S1-S5.
https://doi.org/10.1158/0008-5472.SABCS12-S1-5
|
[26]
|
Anderson, E.J., Mollon, L., Dean, J.L., et al. (2018) A Systematic Literature Review of the Clinical Prognosis of HR+/ HER2-Advanced or Metastatic Breast Cancer with and without PIK3CA Mutation. Journal of Clinical Oncology, 36, e13037. https://doi.org/10.1200/JCO.2018.36.15_suppl.e13037
|
[27]
|
Ellis, M.J., Lin, L., Crowder, R., et al. (2010) Phos-phatidyl-inositol-3-kinase Alpha Catalytic Subunit Mutation and Response to Neoadjuvant Endocrine Therapy for Estro-gen Receptor Positive Breast Cancer. Breast Cancer Research and Treatment, 119, 379-390. https://doi.org/10.1007/s10549-009-0575-y
|
[28]
|
Cardoso, F., Senkus, E., Costa, A., et al. (2018) 4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4). Annals of Oncology, 29, 1634-1657. https://doi.org/10.1093/annonc/mdy192
|
[29]
|
Vasan, N., Toska, E. and Scaltriti, M. (2019) Overview of the Rele-vance of PI3K 19 Pathway in HR-Positive Breast Cancer. Annals of Oncology, 30, x3-x11. https://doi.org/10.1093/annonc/mdz281
|
[30]
|
Dresman, D., Yan, H., Traverso, G., et al. (2003) Transforming Sin-gle DNA Molecules into Fluorescent Magnetic Particles for Detection and Enumeration of Genetic Variations. Proceed-ings of the National Academy of Sciences of the United States of America, 100, 8817-8822. https://doi.org/10.1073/pnas.1133470100
|
[31]
|
Diehl, F., Li, M., Dressman, D., et al. (2005) Detection and Quanti-fication of Mutations in the Plasma of Patients with Colorectal Tumors. Proceedings of the National Academy of Sciences of the United States of America, 102, 16368- 16373. https://doi.org/10.1073/pnas.0507904102
|
[32]
|
Mosele, F., Stefanovska, B., Lusque, A., Tran Dien, A., Garberis, I., Droin, N., Le Tourneau, C., Sablin, M.P., Lacroix, L., Enrico, D., et al. (2020) Outcome and Molecular Landscape of Patients with PIK3CA-Mutated Metastatic Breast Cancer. Annals of Oncology, 31, 377-386. https://doi.org/10.1016/j.annonc.2019.11.006
|
[33]
|
Mollon, L.E. anderson, E.J., Dean, J.L., Warholak, T.L., Aizer, A., Platt, E.A., Tang, D.H. and Davis, L.E. (2020) A Systematic Literature Review of the Prognostic and Predictive Value of PIK3CA Mutations in HR(+)/HER2(−) Metastatic Breast Cancer. Clinical Breast Cancer, 20, e232-e243. https://doi.org/10.1016/j.clbc.2019.08.011
|
[34]
|
Juric, D., Ciruelos, E., Rubovszky, G., et al. (2019) Abstract GS3-08: Alpelisib + fulvestrant for Advanced Breast Cancer: Subgroup Analyses from the Phase III SOLAR-1 Trial. Gen Sess. Abstr., American Association for Cancer Research, Philadelphia, GS3-08-3. https://doi.org/10.1158/1538-7445.SABCS18-GS3-08
|
[35]
|
Andre, F., Ciruelos, E., Rubovszky, G., et al. (2019) Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer. The New England Journal of Medicine, 380, 1929-1940.
https://doi.org/10.1056/NEJMoa1813904
|
[36]
|
Ramirez-Ardila, D.E., Helmijr, J.C., Look, M.P., et al. (2013) Hotspot Mutations in PIK3CA Associate with First-Line Treatment Outcome for Aromatase Inhibitors But Not for Ta-moxifen. Breast Cancer Research and Treatment, 139, 39-49. https://doi.org/10.1007/s10549-013-2529-7
|
[37]
|
Stemke-Hale, K., Gonzalez-Angulo, A.M., Lluch, A., et al. (2008) An Integrative Genomic and Proteomic Analysis of PIK3CA, PTEN, and AKT Mutations in Breast Cancer. Cancer Re-search, 68, 6084-6091.
https://doi.org/10.1158/0008-5472.CAN-07-6854
|
[38]
|
Maruyama, N., Miyoshi, Y., Taguchi, T., et al. (2007) Clinicopathologic Analysis of Breast Cancers with PIK3CA Mutations in Japanese Women. Clinical Cancer Research, 13, 408-414.
https://doi.org/10.1158/1078-0432.CCR-06-0267
|
[39]
|
Beelen, K., Opdam, M., Severson, T.M., et al. (2014) Phosphorylated p-70S6K Predicts Tamoxifen Resistance in Postmenopausal Breast Cancer Patients Randomized between Adjuvant Tamoxifen versus No Systemic Treatment. Breast Cancer Research, 16, R6. https://doi.org/10.1186/bcr3598
|
[40]
|
Kalinsky, K., Jacks, L.M., Heguy, A., et al. (2009) PIK3CA Mutation Asso-ciates with Improved Outcome in Breast Cancer. Clinical Cancer Research, 15, 5049-5059. https://doi.org/10.1158/1078-0432.CCR-09-0632
|